Colorectal cancer: A study approved by Anvisa has seen unprecedented results in eliminating tumors in 100% of cases. “During the mean 12-month period, no patients received chemoradiotherapy and no patients underwent surgical resection.”
The drug, already approved by Anvis, surprised the scientific community by eliminating colon cancer in 100% of patients undergoing treatment. The test, which confirmed the surprising research, came from a small group of 12 patients with rectal cancer. In them, the researchers topically applied a monoclonal antibody called dostarlimab, which led to an encouraging outcome and lasted for more than a year.
The study was published in the New England Journal of Medicine on Sunday, May 5, and was discussed by oncologists during the annual event of the American Society of Clinical Oncology (ASCO), which ended Tuesday, July 7. After treatment, examinations such as magnetic resonance imaging , endoscopic evaluation, digital rectal examination or biopsy showed no evidence of tumor presence.
Patients took the drug intravenously every three weeks for six months. “During the mean follow-up period of 12 months, no patient received chemoradiotherapy and no patient underwent surgical resection,” the study excerpt said.
In an interview with The New York Times, oncologist Louise Diaz Jr., one of the authors of the paper, says that the success rate of American research is not common, and that this may be the first time such a thing has been recorded in the whole country.
“I don’t think anyone has seen this before, where every patient’s tumor has disappeared,” said oncologist from the Sloan Kettering Memorial Cancer Center in New York and lead author of the study Andrea Cercek.
Dostarlimab has been approved in Brazil for the treatment of endometrial cancer and has not been tested for other types of tumors until then. Although promising, the study has some caveats, such as the need for long-term follow-up to see if tumors will not recur or if metastases will not occur in other parts of the body.
It is also worth noting that all volunteers had a specific abnormality in their rectal cancer, popularly known as ‘lack of repair mismatch’, which prevents normalization of bodily function and results in cellular mutations. This type of abnormality occurs between 5 and 10% of all patients with rectal cancer.
Patients with rectal cancer have a high survival rate, but conventional treatment can have lifelong consequences. Examples of consequences are: bowel and bladder dysfunction, sexual dysfunction, and even infertility in younger women. Some patients may still need to carry a colostomy bag permanently.
→ IF YOU DID HERE … consider helping Pragmatism continue the work it has been doing for 13 years, reaching millions of people. Our journalism has always bothered many, but attempts to silence it have increased since Jair Bolsonar came to power. So it never made so much sense to ask for your support. Every contribution is important and helps maintain the team, structure and freedom of expression. Click here and support!